Stock Ratings / Health Care / AKTS / dividends

KURA (32) ORIC (29) CYRX (43) ANRO (35) ⌘ Pro Terminal →

Aktis Oncology Inc. (AKTS) Dividend Safety Gauge & 10-Year DRIP Compounder

$16.85 +0.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.82

Aktis Oncology Inc. (AKTS) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $937.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AKTS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Aktis Oncology Inc. (NASDAQ: AKTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $16.85 (+0.18% 1D, market cap $937.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AKTS ranks #499 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AKTS compare to KURA and ORIC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTS carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KURA (Kura Oncology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and ORIC (Oric Pharmaceuticals Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AKTS?

▼

Per AKTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002035832), Aktis Oncology Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $264.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $16.82 (-0.16%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AKTS)Realized 20D OHLCV Swing Band: ±11.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY AKTS SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0.7% FCF Margin ($26.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$17.34-12.9% Next Q

Q2 (-2Q)

Grade D$15.11+4.1% Next Q

Q3 (-1Q)

Grade D$15.73+7.1% Next Q

Current

Grade D-$16.85-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AKTS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AKTS currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.43) and Max Pain ($17.69) forces dealer call-delta covering toward $35.90.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AKTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AKTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AKTS)

✓Walkthrough of AKTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AKTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.32%▼ DESCENDING CHANNEL

2026-11-02O $16.82H $16.85L $16.82C $16.85VOL 245.7K

RES: $21.84SUP: $13.66SMA50: $20.43SMA200: $21.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AKTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AKTS Butterfly Map → + Track AKTS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AKTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AKTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AKTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AKTS)

Health Care Rank #499 of 1016 ⚔️ KURA vs AKTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AKTS vs. KURA, ORIC, CYRX, ANRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aktis Oncology Inc. (AKTS) ranks #499 by composite RQD confidence (41/100, grade D-) and #369 by equity capitalization ($937.2M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. CYRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with AKTS at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AKTS ACTIVE Aktis Oncology Inc.	D-	41/100	—	—	—	+0.18%	$937.2M	Benchmark Subject
KURA Kura Oncology Inc.	E	32/100	—	—	-35.0%	-1.49%	$939.4M	/kura-vs-akts →
ORIC Oric Pharmaceuticals Inc.	E	29/100	—	—	-33.4%	-3.33%	$931.8M	/oric-vs-akts →
CYRX CryoPort Inc.	D-	43/100	11.8x	47.1%	-11.5%	-1.88%	$926.4M	/cyrx-vs-akts →
ANRO Alto Neuroscience Inc.	D-	35/100	—	—	-35.0%	+0.60%	$921.0M	/anro-vs-akts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002035832

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aktis Oncology Inc. (AKTS) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, AKTS closed FY2025 with $264.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$264.9M	—

3. AKTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AKTS compare to KURA and ORIC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AKTS?

Where is AKTS trading relative to its 50-day, 200-day, and 52-week technical levels?

AKTS last traded at $16.85 (+0.18% on volume of 245,686 shares), positioning the stock -17.52% below its 50-day simple moving average ($20.43) and -19.76% below its 200-day simple moving average ($21.00). Across its 52-week range of $14.72 to $34.19, AKTS sits at the 10.9% percentile with a 14-day RSI of 44.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.5% ($14.91 to $18.79).

AKTS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does AKTS pay a dividend and is it safe?

Aktis Oncology Inc. (AKTS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: AKTS RQD Cockpit AKTS 12M Forecast AKTS Earnings & Move AKTS Dividends & DRIP AKTS Insiders & 13F AKTS Whale Options AKTS Profit Sankey AKTS News & Why